110 results about "Dammarane" patented technology

The invention provides a use of dammarane-type triterpene derivatives represented by general formula I or pharmaceutically acceptable salts thereof, and a use of a medicinal composition containing the derivatives or the pharmaceutically acceptable salts thereof, and a plant extract product. The dammarane type triterpene derivatives, the medicinal composition and the plant extract product can activate AMPKalpha2beta1gamma1 at the molecular level, and can be used to prepare AMPK micromolecule activators in order to prepare medicines for preventing or treating AMPK related diseases.

The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions and methods for modulating beta-amyloid protein production, including Aβ42 in a cell. The invention further provides compositions and methods for treating and preventing neurodegeneration by administering to a subject an effective amount of a dammarane or ginsenoside compound. Additionally, the invention provides kits for use in treating and/or preventing Alzheimer's disease and neurodegeneration, as well as for reducing the production of beta-amyloid protein.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

The invention relates to saponin compounds or pharmaceutically acceptable salts thereof, compositions, and a preparation method of the saponin compounds or the pharmaceutically acceptable salts thereof, and application of the saponin compounds or the pharmaceutically acceptable salts therof and the compositions. Chemical components of gynostemma pentaphylla are subjected to systematic extraction,separation and purification by using various column chromatographic separation methods, and the compound having a dammarane tetracyclic triterpenoid structures and containing a glycosyl group in a side chain is obtained through separation. The compounds obtained by separation according to a technical scheme in the invention have anti-inflammatory, anti-tumor, antioxidant and lipid-lowering activities and the like.

This invention relates to a group of novel sapogenins, their use in anti-cancer applications, and to a process for their production. More particularly, this invention pertains to a novel group of dammarane sapogenins, PAM-120, PBM-110 and PBM-100 (the dammarance sapogenine structure is specifically clean of any sugar moieties (glycons) at any position and hydroxyl at C-20) and PAN-20 and PAN-30 (the dammarance sapogenin structure has sugar moieties but is free of hydroxyl at C-20), obtained by chemical cleavage of dammarane saponins. The invention also includes a novel application of the said sapogenins for anti-cancer treatment by using them separately or together, and/or jointly with other drugs, as well as to the process of producing these novel sapogenins. Said novel dammarane sapogenins show surprising anti-cancer effect when applied, particularly against multi-drug resistant cancers.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 3-O-beta-D-glycopyranoside-dammarane-24-alkenyl-3beta, 12beta, 20(S)-triol compound in the field of pharmacy. The compound can effectively confront reserpine related ptosis or akinesia, L-5-HT related mouse tremble, mouse suspension tail or forced swimming acquired desperation and depression and enhance levodopa behavioral effects under test dose, and has no excitation or inhibition function on central pivot. The safety research shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system, and has no mutagenesis function. The compound has high safety and good antidepressant function under the test dose, and the action mechanism of the compound can block the reuptake of NA and DA transmitter so as to increase the concentration correlation of two transmitters of synapse and clearance; and the compound can be used for treating depression.

The invention belongs to a filed of medicine technology, which relates to a novel pair of panaxsapogenol and a medical application of a mixture thereof. The pair of compounds are 20(R)-25-methoxyl-dammarane-3beta, 12beta, 20-triol(25Rmdt for short) and 20(S)-25-me-thoxyl-dammarane-3beta, 12beta, 20-triol(25Smdt for short). The 25Rmdt and 25Smdt and the mixture thereof have the antitumor activities of inhibiting the growth and multiplication of a plurality of tumor cells, inducing the differentiation and withering of tumor cells, inhibiting the generation of tumor angiogenic blood vessels, inhibiting the invasion and transfer of tumors, enhancing the body immunity and reducing the toxic and side effects of chemotherapeutic drugs, which is substantially used for treating malignant tumors, with a total effective dosage of 1-100mg/kg/d.

The invention provides a method for preparing protopanoxadiol derivatives of a formula below, namely 20(R)-25-hydroxy-dammarane type-3beta,12beta,20-triols[abbreviated as 20(R)-25-OH-PPD]. The protopanoxadiol derivatives are obtained by hydrolyzing total ginsenoside, wherein the method for hydrolyzing the total ginsenoside comprises a basic hydrolysis process, an acid hydrolysis process I and an acid hydrolysis process II. The structure of the 20(R)-25-hydroxy-dammarane type-3beta,12beta,20-triols is determined by nuclear magnetic resonance spectrum. The method is high in yield and purity, ensures stable product quality and can realize industrial production and can meet the needs for development of new antitumor medicines.

The invention provides a preparation method of the original protopanaxadiol derivative with the structure as 20 (R)-25-hydroxy-dammarane-3beta, 12beta, 20- triol [for short 20 (R)-25-OH-PPD]. The silica gel chromatography and the total ginsenoside hydrolysis are used to make the original protopanaxadiol derivative; therein, the ginsenoside hydrolysis includes the alkali water hydrolysis the acid hydrolysis I and the acid hydrolysis II. The NMR spectrum is used to determine the structure. The method is of the high collection rate, the high purity and the stable quality of the products; the invention can realize the industrial production, and can meet the development requirements of the novel anti-tumor drugs.

The invention relates to a dammarane aglycon compound and application thereof, in particular to application of oral administration and injection preparations which are prepared by a single dammarane aglycon compound prepared by basic hydrolysis by utilizing the particular patent technology of the Pegasus Pharmaceuticals Group of Canada by adopting Asian ginseng stem and leave saponin or prepared in the way that the dammarane aglycon compound is matched with other medically permissive auxiliary materials in prevention and treatment on bone marrow suppression caused by different chemotherapy and radiotherapy.

The invention discloses a dammarane triterpene derivative represented by formula (I); a pharmaceutical salt thereof; a preparation method of the dammarane triterpene derivative; a pharmaceutical composition containing the dammarane triterpene derivative as an active ingredient; applications of the dammarane triterpene derivative, the pharmaceutical salt, and the pharmaceutical composition in preparation of medicines used for treating or preventing obesity, diabetes, hypertension, cardiovascular and cerebrovascular diseases, and related metabolic diseases; and applications of the dammarane triterpene derivative, the pharmaceutical salt, and the pharmaceutical composition in preparation of 11<beta>-HSD1 inhibitor.

The invention discloses dammarane triterpenoid glycoside compounds as well as a preparation method and application thereof. The dammarane triterpenoid glycoside compounds are specifically three compounds which are separated from a rubiaceae rubia plant, namely Mycephala sinensis (Hemsl.) Craib, and the structural formula of the dammarane triterpenoid glycoside compounds is shown in the specification. Tests show that the dammarane type triterpenoid saponin with the structure shown in the formula 2 has sweetness, the sweetness of the dammarane type triterpenoid saponin is about 200 times that ofcane sugar, and the dammarane type triterpenoid saponin can be used as a sweetening agent and applied to various industries such as food and medicines.

The invention relates to a dammarane type triterpene glycoside compound obtained by extracting and separating from tetraploid gynostemma pentaphyllum, and a preparation method and application of the dammarane type triterpene glycoside compound. The compound, and optical isomers, medicinal salt derivatives and solvates of the compound have a purpose of preparing an anti-inflammatory drug, can be applied in self-forms, and can also be applied by forming drug compositions with acceptable carriers in pharmacy; the preparation method is simple and easy to operate; and the obtained compound is high in purity, and has a good economic benefit and an industrial application prospect.

The invention relates to a new Camellia nitidissima saponin A compound separated from Camellia nitidissima and a preparation method thereof, and application of the compound in tumor resistance. The dammarane saponin new compound is separated from Camellia nitidissima. The new compound is named (3beta,6alpha,12beta)-3,6,12-trihydroxydammaryl-24-alkenyl-20-methyl-2-O-beta-D-glucopyranosyl-(2->1)-O-beta-D-glucopyranosyl-(2->1)-O-alpha-L-pyranylrhamnosido[(3beta,6alpha,12beta)-3,6,12-trihydroxydammar-24-en-20-yl-2-O-beta-D-glucopyranosyl-(2->1)-O-beta-D-glucopyranosyl-(2->1)-O-alpha-L-Rhamnopyranoside]. A CCk-8 process is utilized to carry out antitumor activity detection on the new compound; and the experimental result indicates that the compound has the activities for inhibiting human lung cancer BeL-7402 cells, SMMC-7721 and the like from growth.

The invention discloses a method for producing low-polarity ginsenoside. The method comprises the following steps: performing catalytic decomposition of the raw materials: a ginsenoside-containing plant, a tissue culture of the plant, an extract of the plant and/or natural ginsenoside; and heating and separating to obtain the low-polarity ginsenoside. By adopting the ginseng processing method disclosed by the invention, 25-hydroxyl dammarane and 25-dammarene can be produced; and by carefully controlling the catalytic decomposition process, the output and composition of the extracted ginsenoside are controllable, and the yield of the target product extracted from the raw materials such as treated ginseng is high.

The present invention provides novel dammarane compounds, compositions (e.g., pharmaceutical compositions) comprising the dammarane compounds, and methods for the synthesis of these dammarane compounds. Additionally, the present invention provides methods for inhibiting beta-amyloid peptide production and methods for treating or preventing a pathological condition, particularly, neurodegeneration diseases (e.g., Alzheimer's disease), using these dammarane compounds.

The invention belongs to the technical field of medicines and relates to an anti-hepatic fibrosis medical application of dammarane type sapogenin 20(R)-25-methoxy-dammarane-3beta,12beta,20-triol and 20(R)-25-hydroxyl-dammarane-3beta,12beta,20-triol (which are called as 25-OCH3-PPD and 25-OH-PPD for short). Study shows that 25-OCH3-PPD and 25-OH-PPD can be used for reducing expression of alpha-SMA, TGF-beta and TIMP-1, improving caspase-3 level and increasing signal paths for NF-kappaB redistribution and generation of Bcl-2 proteins in hepatic stellate cells, and the hepatic stellate cells are reversed to be in a resting state, so that hepatic fibrosis is reversed, and 25-OCH3-PPD and 25-OH-PPD can be used for preparing a medicine for treating the hepatic fibrosis.

The invention discloses a 3,4-dammarane tetracyclic triterpenoid compound with the structural formula shown in formulas (1)-(4). The invention further discloses an extraction method and application ofthe 3,4-dammarane tetracyclic triterpenoid compound. The 3,4-dammarane tetracyclic triterpenoid compoundcan significantly increase the consumption of insulin resistance adipocyte glucose, inhibit generation of IR adipocyte FFA, reduce the content of free fatty acid in cells and activate PPAR<gamma> to a certain extent.

The invention pertains to the field of medical technology, which relates to a pair of new ginsengenins, the preparation method of the mixture thereof (raceme) and a novel anti-tumor preparation which contains the compounds as active ingredients. The names of the pair of compounds are 20(R)-25-methoxyl-dammarane-3 Beta, 12 Beta, 20-triol(known as 25Rmdt for short) and 20(S)-25-methoxy-dammarane-3 Beta, 12 Beta, 20-triol(known as 25Smdt for short). The compounds of the invention can be prepared by adopting acid hydrolysis method, alkaline hydrolysis method and synthesis method, and the preparation method is simple and feasible. The 25Rmdt, the 25Smdt, the mixture (raceme) and a pharmaceutically acceptable carrier can be made into the clinical feasible various formulations, studies prove that: the compounds and the preparations have significant anti-tumor effects, and can be made into any medicinal and health care formulation for the treatment of different cancers and be mainly applied in the prevention and the treatment of malignant tumors with the broad application prospect.

The invention provides the application of a dammarane triterpenes derivative with the structure shown as the following formula (I), a drug composition containing the dammarane triterpenes derivative, and application thereof. The dammarane triterpenes derivative and the drug composition which can induce the apoptosis of hepatic stellate cells can be used for preparing drugs for preventing or treating hepatic fibrosis and hepatocirrhosis.

The invention provides a dammarane type triterpenoid saponin derivative represented in a general formula I, pharmaceutical composition adopting the dammarane type triterpenoid saponin derivative as an active ingredient, and applications of the dammarane type triterpenoid saponin derivative in preparation of drugs for treating neurological diseases and Alzheimer's disease. R1 in the formula I is hydrogen or glycosyl, R2 is hydrogen or glycosyl, and R3 is the C-20-C-27 site of a dammarane type triterpenoid C17-site side chain.

The invention discloses a cultivation method of a novel dammarane-type ginsenoside-containing paddy rice variety and belongs to the field of genetic engineering. The breeding method is characterized in that a full-length cDNA of a gene of a dammarenediol synthetase as a key enzyme of dammarane-type ginsenoside biosynthesis is constructed to double-T-DNA plant expression vectors; the constructed product is subjected to genetic transformation in paddy rice; and through screening cultivation, the novel dammarane-type ginsenoside-containing paddy rice variety is obtained. A test proves that the novel dammarane-type ginsenoside-containing paddy rice variety comprises 0.020% of 20(S)-protopanoxadiol (PPD) and 0.173% of 20(S)-protopanaxatriol (PPT). The cultivation method can be used for cultivation of high-quality ginseng rice varieties containing dammarane-type ginsenoside, can improve a health care value of rice as a main food of a human body, can widen a ginsenoside source, can alleviate the scarcity of a ginsenoside drug source, and has a good application prospect.